The association of biomarkers with patient survival after recurrence (SAR) of cancer is poorly understood but may guide management and treatment. 
P rognostic biomarkers in patients with tumor recurrence have the potential to influence management and treatment decisions. Approximately 30% of patients with stage III colon carcinoma will experience recurrence of their disease despite adjuvant chemotherapy. 1 2 However, the association of biomarkers with survival after recurrence (SAR) remains poorly understood, and studies have been underpowered given the relatively low frequency of these alterations and modest rates of tumor recurrence.
In patients with stage III tumors who participated in adjuvant chemotherapy trials, those whose tumors showed deficient MMR (dMMR) or microsatellite instability (MSI) have generally had better clinical outcomes compared with those with proficient MMR (pMMR) or microsatellite stability. 3 However, the association of dMMR or MSI with prognosis is less robust in stage III vs stage II disease, 4 and limited data exist in patients treated with the adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) regimen in contrast to fluorouracil alone. [5] [6] [7] [8] As with metastatic disease, 9 BRAF
V600E
mutations have been shown to be significantly associated with poorer survival, 10-12 with a stronger impact seen for overall survival compared with disease-free or progression-free survival 13 for reasons that remain unclear. Because BRAF V600E mutations are significantly enriched in sporadic colon cancers with dMMR or MSI (owing to epigenetic inactivation of MLH1), 14, 15 the combined MMR BRAF variable may be more informative than either alone. In this regard, a new consensus guideline for the molecular testing of colorectal cancer recommends that BRAF be analyzed in conjunction with MMR for prognostic stratification. Data for the association of a KRAS mutation with clinical outcome have been less consistent than for a BRAF V600E mutation. 13, [16] [17] [18] In participants in the North Central Cancer Treatment Group (NCCTG) N0147 16 and the Pan European Trial Adjuvant Colon Cancer-8 (PETACC-8) adjuvant chemotherapy trials, 19 stage III colon cancers with mutant vs wildtype (WT) KRAS had poorer rates of disease-free survival.
We studied the association of MMR and mutations in BRAF V600E or KRAS in the primary tumor with SAR in participants in the NCCTG N0147 and the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-08 adjuvant chemotherapy trials. These trials evaluated FOLFOX chemotherapy alone or combined with cetuximab (N0147) 20 or bevacizumab (NSAPB C-08), 21 wherein neither antibody significantly improved patient outcome vs FOLFOX chemotherapy alone. We also determined whether the association of biomarkers with SAR depended on the primary tumor site within the colon given recent data suggesting prognostic differences by tumor site.
6,22
Methods
The study population consisted of patients with stage III adenocarcinoma of the colon who developed recurrence during participation in the phase III adjuvant chemotherapy studies NCCTG N0147 (n = 871) 20 and NSABP C-08 (n = 524). 21 The analysis was prespecified in the study protocols. We categorized primary tumor site as proximal to or at or distal to the splenic flexure. 
Molecular Testing
We collected data from February 10, 2004, to August 7, 2015. The DNA MMR proteins MutL protein homolog 1 (MLH1), MutS protein homolog 2 (MSH2), and MutS protein homolog 6 (MSH6) were analyzed in formalin-fixed, paraffin-embedded tumor tissues from the N0147 trial as previously described 10 ; MLH1 and MSH2 expression were analyzed in tumors from the C-08 trial as reported. 23 Loss of MMR protein was defined as the absence of nuclear staining in tumor cells in the presence of nuclear staining in normal colonic epithelium and lymphocytes. Tumors with loss of an MMR protein were categorized as having dMMR and those with intact expression as having pMMR. All biomarker assays were interpreted with investigators blinded to patient outcomes. Mutation status of BRAF V600E and KRAS were determined using genomic DNA extracted from macrodissected formalin-fixed, paraffin-embedded tumor tissue collected prospectively. In the N0147 trial, testing for the BRAF V600E mutation in exon 15 was performed using a multiplex allelespecific, polymerase chain reaction-based assay and an automated sequencing technique, as previously described.
10
Mutation status in KRAS exon 2 was analyzed using a KRAS mutation kit (DxS; TheraScreen) assessing for 7 different mutations in codons 12 and 13. 16 In the N0147 trial, molecular analyses were performed in a Clinical Laboratory Improvement Amendments-compliant laboratory. Mutation profiling of tumor specimens from the C-08 trial was performed using , but not KRAS, were associated with shorter survival after recurrence in the overall cohort.
Meaning DNA mismatch repair and BRAF mutations can provide prognostic information in patients with tumor recurrence.
Statistical Analysis
Survival after recurrence, defined as the time from recurrence to death from any cause, was the primary study outcome. Owing to the potential for significant confounding, all analyses were based on multivariable models that were adjusted for clinicopathologic variables, time to recurrence (TTR), and biomarkers. The distribution of SAR between patient subgroups by biomarkers was estimated based on direct adjusted survival curves.
24-26 Because initial results showed significant differences in SAR among the 4 arms of the 2 adjuvant chemotherapy trials (P = .03), multivariable Cox proportional hazards models (stratified by the 4 treatment groups) were applied to assess the effect of biomarkers on SAR among patients with recurrence. Models were adjusted for age, sex, performance score, initial T/N stage, histologic grade, time from initial treatment to recurrence, primary tumor site, and biomarkers when applicable. The proportional hazards assumption was confirmed by examination of the Schoenfeld residuals plot. 27 We determined the interaction effects of the primary tumor site with the effect of biomarkers on SAR. Subgroup analyses were performed when statistically significant interaction effects were present. Association analyses were performed in patients from the modified sixth version of FOLFOX (mFOLFOX6)-alone treatment arms from both studies owing to clinical relevance. Two-sided P values are reported; P <.05 was considered statistically significant and was not adjusted for multiple comparisons. Analyses were performed using SAS software (version 9.4; SAS Institute Inc).
Results
Among the adjuvant trial participants, 3018 patients received mFOLFOX6 with or without cetuximab (N0147 trial) 20 KRAS genes ( Figure 1 ).
Molecular Markers and SAR
The multivariable associations of patient demographics and clinicopathologic features, adjusted for biomarkers (MMR, KRAS, and BRAF), with SAR are presented in Table 1 . Patients with distal tumors had significantly better SAR than did patients with proximal tumors (adjusted hazard ratio [AHR], 0.70; 95% CI, 0.58-0.84; P < .001). Longer TTR after primary resection was associated with significantly better SAR (AHR for 1-year delay, 0.79; 95% CI, 0.72-0.87; P < .001) ( Table 1 ). In addition, a significant association with SAR was found for patient performance score (AHR, 1.23; 95% CI, 1.01-1.49; P = .04), N stage (AHR, 1.39; 95% CI, 1.17-1.66; P < .001), and histologic grade (AHR, 1.40; 95% CI, 1.17-1.68; P < .001). Among patients who experienced recurrence, those whose tumors showed pMMR vs dMMR (AHR, 1.71; 95% CI, 1.32-2.21; P < .001) or had WT KRAS (AHR, 1.22; 95% CI, 1.05-1.14; P = .01) and WT BRAF (AHR, 1.47; 95% CI, 1.17-1.83; P < .001) vs either mutated gene had significantly longer median TTR (eTable 1 in the Supplement). Multivariable associations of molecular markers with SAR are shown in Table 2 . After adjustment for covariates, including TTR after primary treatment, patients with dMMR vs pMMR tumors had significantly better SAR (AHR, 0.70; 95% CI, 0.52-0.96; P = .03) ( Figure 2A and Table 2 ). Patients whose tumors had mutant BRAF V600E had significantly worse SAR compared with those whose tumors had WT BRAF (AHR, 2.45; 95% CI, 1.85-3.25; P < .001) ( Figure 2B and C and shorter SAR compared with pMMR and WT BRAF (median, 28.4 months; 95% CI, 26.2-31.9 months) ( Table 2 and Figure 2D ). In contrast, patients showed better adjusted median SARs of 30.3 (95% CI, 21.4 to not reached) if their tumor had dMMR with WT BRAF and 28.4 (95% CI, 26.2-31.9) months if their tumor had pMMR with WT BRAF, with no statistical difference (P = .43) between these 2 groups (Table 2 and Figure 2D ). Within the subset of dMMR tumors, we observed that those with BRAF mutations had significantly poorer SAR compared with those with WT BRAF (AHR, 2.70; 95% CI, 1.23-5.93; P = .01) ( 
Analysis by Primary Tumor Site
Based on statistically significant interactions between biomarkers and primary tumor site for SAR (Table 2) , we separately examined the associations between biomarkers and SAR among patients with proximal or distal tumors (Table 3 and eFigure in the Supplement). After adjustment for covariates, patients with dMMR tumors of the proximal but not the distal colon had significantly better SAR (AHR, 0.57; 95% CI, 0.40-0.83; P = .003) (Table 3 and eFigure, A in the Supplement), with P = .03 for interaction (Table 2) . Patients with BRAF V600E -mutated tumors had significantly shorter SAR for proximal tumors (AHR, 1.90; 95% CI, 1.37-2.64; P < .001) (eFigure, D in the Supplement) and distal tumors (AHR, 5.84; 95% CI, 3.27-10.43; P < .001) vs those whose tumors had WT BRAF (eFigure, B in the Supplement)orWTBRAF and WT KRAS (eFigure, C in the Supplement) (Table 3) , although the interaction between BRAF and primary tumor site for SAR did not achieve statistical significance (P = .056) ( Table 2) . A significant interaction test was observed for KRAS mutations (codons 12 and 13) (P = .02) and the combined KRAS-BRAF variable (P < .001) with primary tumor site for SAR ( 
Analysis by Study Treatment Arm
A statistically significant interaction was observed between the study treatment arm and MMR status (P = .003) and for the combined variable of MMR and BRAF (P = .02) for SAR ( 
Discussion
We determined the effect of biomarkers on SAR in patients with stage III colon cancer who participated in 2 large adjuvant chemotherapy trials of FOLFOX-containing therapy. In the overall cohort, patients whose tumors had mutant BRAF had significantly worse SAR, with a 14.2-month decrease in adjusted median survival time compared with patients whose tumors had WT BRAF. This result can explain, at least in part, prior data showing that mutant BRAF V600E was more strongly associated with overall survival compared with disease-free survival or relapse-free survival in the N0147 6 and PETACC-3 adjuvant chemotherapy trials. 13 Furthermore, these findings suggest that the effect of BRAF V600E mutation on tumor aggressiveness is enhanced at the time of tumor recurrence Among patients with dMMR tumors, we found that their adjusted median SAR was 7 months longer than that for patients with pMMR tumors, indicating a clinically significant survival advantage for this patient subset. This finding is consistent with the longer recurrence-free interval (ie, TTR) observed for dMMR vs pMMR tumors in the overall study cohort. The analysis was adjusted for covariates that included BRAF mutation status, TTR, and primary tumor site, which were the variables whose inclusion in the multivariable model had the greatest effect on SAR in dMMR tumors. The longer SAR for patients with dMMR tumors may be explained, in part, by the increase in recurrence rates at regional vs distant sites, such as the liver, that was observed in the N0147 cohort.
28 Among patients whose tumors had mutant KRAS, a poorer SAR that did not reach statistical significance was observed for codon 12 or 13 mutations. Sporadic colon cancers with dMMR are highly enriched with BRAF V600E mutations, 5,14 and a forthcoming consensus guideline 30 recommends that BRAF V600E mutation testing be performed in conjunction with MMR analysis for prognostic stratification. A similarly poor SAR was observed for patients with BRAF
V600E
-mutant dMMR cancer (adjusted median SAR, 14.5 months; 95% CI, 11.8-45.9 months) and pMMR cancers (adjusted median SAR, 15.4 months; 95% CI, 10.8-16.7 months). In contrast, patients whose tumors had WT BRAF showed significantly better adjusted median SARs of 30.3 months (95% CI, 21.4 months to not reached) for dMMR and 28.4 months (95% CI, 26.2-31.9 months) for pMMR cancers. Therefore, the mutational status of BRAF is an important determinant of SAR that confers adverse outcomes in patients with dMMR and pMMR cancers. In a pooled analysis of patients with stage II colon cancers, although the analysis was not adjusted for BRAF. The authors, however, postulated that the association of dMMR with shorter SAR was due to mutant BRAF V600E because patients with mutant BRAF V600E tumors had a significantly shorter SAR. 23 In another study of patients with stages I to IV colorectal cancers, 31 transcriptomic data were used to categorize tumors into 4 consensus molecular subtypes (CMSs). The CMS I subtype was enriched for tumors with high-frequency MSI and BRAF V600E mutations, and patients with these tumors had a poorer SAR compared with the other 3 subtypes (CMS I-III) by univariate analysis. 31 However, the study data used to generate CMSs were not adjusted for BRAF (or KRAS) status or for TTR, which was strongly associated with SAR as shown in our data set. We observed a statistically significant interaction between biomarkers (MMR and KRAS) and the primary tumor site for SAR. The significant association of dMMR with better SAR was limited to cancers of the proximal vs distal colon. Although not prognostic overall, analysis of KRAS mutations by primary tumor site revealed a significantly shorter SAR for patients with distal but not proximal cancers. This finding for SAR is consistent with TTR data from the N0147 cohort, in which the association of KRAS mutations with TTR and overall survival was stronger in patients with distal cancers.
6 Conversely and relevant to anti-epidermal growth factor receptor therapy, patients whose tumors had WT KRAS alleles had significantly better SAR for distal vs proximal cancers. However, patients with stage III tumors with WT KRAS treated with FOLFOX + cetuximab vs FOLFOX alone had similar SAR, irrespective of tumor site. In patients with metastatic colorectal cancer, a recent report suggests that distal cancers respond more favorably to cetuximab than do proximal tumors (CALGB [Cancer and Leukemia Group B] 80405). 32 Patients whose tumors harbored BRAF V600E mutations had significantly poorer SAR independent of primary site, but the association was stronger for distal tumors. In this report, an association between the primary tumor site and SAR was also seen in patients with stage III colon cancer treated with nonoxaliplatin-containing chemotherapy in the PETACC-3 study. 33 Factors not studied in our report that may contribute to observed differences in prognosis by tumor site include epigenetic 16 and/or other genomic 33 alterations that may be embryologically influenced because the origin of the proximal colon is from the midgut and that of the distal colon is from the hindgut. In addition, gut microbial composition or metabolites may be relevant factors. Analysis of the associations between biomarkers and SAR by study treatment arm revealed that the better SAR for patients with dMMR tumors seen among FOLFOX-treated patients did not extend to those who also received cetuximab for reasons that are unclear. Owing to the modest number of patients with complete biomarker data in the C-08 trial, results for SAR from the FOLFOX + bevacizumab study arm are not reported.
Strengths and Limitations
Strengths of our study include the 2 clinical trial cohorts receiving standard adjuvant FOLFOX-based chemotherapy with mature recurrence and survival data. All molecular analyses were performed on prospectively collected biospecimens. 
Conclusions
The association of dMMR with more favorable SAR suggests that some of these patients may be candidates for an aggressive surgical approach at recurrence. Furthermore, therapy with an immune checkpoint inhibitor is a new therapeutic option in patients with metastatic dMMR or MSI colorectal cancers, in which impressive tumor response rates and extended progression-free survival were observed. 36 In patients with dMMR and pMMR tumors, BRAF V600E mutations were associated with significantly poorer SAR, indicating the need for novel therapies in this subset. 36,37 The significant interactions of MMR and KRAS mutation status with SAR by primary tumor site indicate that these biomarkers should be interpreted in this context. Taken together, these data have important implications for patients with stage III colon cancer at the time of tumor recurrence, when they can be used to inform clinical decision making.
